Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized Controlled Study of Human Induced Pluripotent Stem Cell-derived Mesenchymal Stromal Cells (iMSC) for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

NCT06949267 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06949267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06949267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized Controlled Study of Human Induced Pluripotent Stem Cell-derived Mesenchymal Stromal Cells (iMSC) for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Ruijin Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 1, 2025
Completion date
March 31, 2028
Enrollment
56 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute graft-versus-host disease